Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative th
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
07:30am, Tuesday, 27'th Jul 2021
PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi
Harmony Biosciences Is Likely To Trade Higher As Wakix Sales Build
01:06pm, Tuesday, 13'th Jul 2021
Harmony Biosciences Is Likely To Trade Higher As Wakix Sales Build
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
08:05am, Tuesday, 29'th Jun 2021
PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative th
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
08:05am, Thursday, 10'th Jun 2021
PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative th
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9
08:05am, Wednesday, 09'th Jun 2021
PLYMOUTH MEETING, Pa., June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative the
Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
08:05am, Monday, 07'th Jun 2021
PLYMOUTH MEETING, Pa., June 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative th
Harmony Biosciences to Participate in Three Investor Conferences in June
07:30am, Wednesday, 26'th May 2021
PLYMOUTH MEETING, Pa., May 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative the
John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors
08:05am, Tuesday, 18'th May 2021
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative the
Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit
07:30am, Tuesday, 18'th May 2021
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative the
Harmony Biosciences: Looking Very Compelling Here
11:00am, Friday, 14'th May 2021
Harmony Biosciences: Looking Very Compelling Here
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs Q1 2021 Earnings Call Transcript
12:45pm, Tuesday, 11'th May 2021
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs Q1 2021 Earnings Call Transcript
Harmony Biosciences Reports First Quarter 2021 Results and Business Updates
08:00am, Tuesday, 11'th May 2021
WAKIX® (pitolisant) Total Revenue of $59.7 Million for First Quarter 2021
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("the Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovat
Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual Meeting
08:05am, Monday, 12'th Apr 2021
PLYMOUTH MEETING, Pa., April 12, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative
